Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.71 USD
−36.32 M USD
0.00 USD
10.28 M
About Neurogene Inc.
Sector
Industry
CEO
Rachel L. McMinn
Website
Headquarters
New York
Founded
2007
FIGI
BBG005Y0QDK1
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NGNE is 71.02 USD — it has increased by 8.75% in the past 24 hours. Watch Neurogene Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Neurogene Inc. stocks are traded under the ticker NGNE.
NGNE stock has risen by 59.55% compared to the previous week, the month change is a 46.01% rise, over the last year Neurogene Inc. has showed a 423.75% increase.
We've gathered analysts' opinions on Neurogene Inc. future price: according to them, NGNE price has a max estimate of 65.00 USD and a min estimate of 44.00 USD. Watch NGNE chart and read a more detailed Neurogene Inc. stock forecast: see what analysts think of Neurogene Inc. and suggest that you do with its stocks.
NGNE reached its all-time high on Aug 10, 2015 with the price of 1,115.00 USD, and its all-time low was 7.50 USD and was reached on Nov 17, 2022. View more price dynamics on NGNE chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NGNE stock is 3.75% volatile and has beta coefficient of 2.24. Track Neurogene Inc. stock price on the chart and check out the list of the most volatile stocks — is Neurogene Inc. there?
Today Neurogene Inc. has the market capitalization of 903.05 M, it has decreased by −9.25% over the last week.
Yes, you can track Neurogene Inc. financials in yearly and quarterly reports right on TradingView.
Neurogene Inc. is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
NGNE earnings for the last quarter are −1.09 USD per share, whereas the estimation was −1.05 USD resulting in a −3.85% surprise. The estimated earnings for the next quarter are −1.22 USD per share. See more details about Neurogene Inc. earnings.
Neurogene Inc. revenue for the last quarter amounts to 925.00 K USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
NGNE net income for the last quarter is −18.49 M USD, while the quarter before that showed −16.92 M USD of net income which accounts for −9.28% change. Track more Neurogene Inc. financial stats to get the full picture.
No, NGNE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 91.00 employees. See our rating of the largest employees — is Neurogene Inc. on this list?
Like other stocks, NGNE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Neurogene Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Neurogene Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Neurogene Inc. stock shows the buy signal. See more of Neurogene Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.